Upon comparison of the distribution of EGCG in mice following oral and intravenous administration, it was observed that the majority of orally administered EGCG entered the bloodstream in its glucuronidated form
PMID 22073434
The European Medicines Agency (EMA) and MHRA continue to monitor adverse event reports for all GLP-1 receptor agonists, including semaglutide
Withdrawal symptoms can also occur when individuals stop taking GLP-1 medications: Reduced side effects: While semaglutide or tirzepatide can lead to side effects like acid reflux, nausea, constipation and abdominal pain, stopping the medication can reduce these side effects
Information about data access request proposals can be found at Change history 28 May 2024 In the version of the article initially published, in Fig
Vossen CY, Conard J, Fontcuberta J, et al